133 related articles for article (PubMed ID: 38566164)
1. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).
Spiliopoulou P; Kazmi F; Aroldi F; Holmes T; Thompson D; Griffiths L; Qi C; Parkes M; Lord S; Veal GJ; Harrison DJ; Coyle VM; Graham J; Jeffry Evans TR; Blagden SP
J Exp Clin Cancer Res; 2024 Apr; 43(1):100. PubMed ID: 38566164
[TBL] [Abstract][Full Text] [Related]
2. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent.
Bré J; Dickson AL; Read OJ; Zhang Y; McKissock FG; Mullen P; Tang P; Zickuhr GM; Czekster CM; Harrison DJ
Cancer Chemother Pharmacol; 2023 May; 91(5):401-412. PubMed ID: 37000221
[TBL] [Abstract][Full Text] [Related]
3. Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Focan C; Levi F; Kreutz F; Focan-Henrard D; Lobelle JP; Adam R; Dallemagne B; Jehaes C; Markiewicz S; Weerts J; Bismuth H; Jasmin C; Misset JL
Anticancer Drugs; 1999 Apr; 10(4):385-92. PubMed ID: 10378673
[TBL] [Abstract][Full Text] [Related]
4. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
5. A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
McNamara MG; Bridgewater J; Palmer DH; Faluyi O; Wasan H; Patel A; Ryder WD; Barber S; Gnanaranjan C; Ghazaly E; Evans TRJ; Valle JW
Oncologist; 2021 Apr; 26(4):e669-e678. PubMed ID: 33210382
[TBL] [Abstract][Full Text] [Related]
6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
Raschko JW; Akman SA; Leong LA; Margolin KA; Morgan RJ; Newman E; Somlo G; Ahn C; Doroshow JH
Cancer Chemother Pharmacol; 1994; 35(2):161-4. PubMed ID: 7987994
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Kortmansky J; Shah MA; Kaubisch A; Weyerbacher A; Yi S; Tong W; Sowers R; Gonen M; O'reilly E; Kemeny N; Ilson DI; Saltz LB; Maki RG; Kelsen DP; Schwartz GK
J Clin Oncol; 2005 Mar; 23(9):1875-84. PubMed ID: 15699481
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.
Chiang NJ; Chao TY; Hsieh RK; Wang CH; Wang YW; Yeh CG; Chen LT
BMC Cancer; 2016 Nov; 16(1):907. PubMed ID: 27871319
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Mani S; Rudin CM; Kunkel K; Holmlund JT; Geary RS; Kindler HL; Dorr FA; Ratain MJ
Clin Cancer Res; 2002 Apr; 8(4):1042-8. PubMed ID: 11948111
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
[TBL] [Abstract][Full Text] [Related]
14. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors.
Saif MW; Sellers S; Diasio RB; Douillard JY
Anticancer Drugs; 2010 Aug; 21(7):716-23. PubMed ID: 20581657
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
16. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors.
Punt CJ; Boni J; Bruntsch U; Peters M; Thielert C
Ann Oncol; 2003 Jun; 14(6):931-7. PubMed ID: 12796032
[TBL] [Abstract][Full Text] [Related]
18. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.
Moore KN; Hong DS; Patel MR; Pant S; Ulahannan SV; Jones S; Meric-Bernstam F; Wang JS; Aljumaily R; Hamilton EP; Wittchen ES; Wang X; Lin AB; Bendell JC
Target Oncol; 2021 Sep; 16(5):569-589. PubMed ID: 34559360
[TBL] [Abstract][Full Text] [Related]
20. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
